Neurotensin Fragments

Overview

Neurotensin (NT) is a 13-amino acid tridecapeptide originally isolated from bovine hypothalamus in 1973 by Robert Carraway and Susan Leeman. Its mature sequence is pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu, and it acts as both a peripheral gut hormone and a central neuropeptide with effects on dopamine transmission, analgesia, thermoregulation, feeding, and cardiovascular function through the receptors NTSR1, NTSR2, and the intracellular sortilin/NTSR3.

A foundational finding in neurotensin research was that the C-terminal hexapeptide NT(8-13) — corresponding to residues 8-13 of the parent peptide — retains full or even enhanced receptor binding and biological activity compared to intact NT. This finding, established in the late 1970s and 1980s, has made NT(8-13) the principal scaffold for medicinal chemistry, drug delivery, and imaging applications of the neurotensin system.

This encyclopedia entry surveys the main neurotensin fragments studied in the literature, their structure-activity relationships, and the stabilized analogs derived from them. Fragments discussed include NT(8-13), shorter C-terminal fragments, N-terminal fragments (largely inactive), and key stabilized analogs such as JMV 449, contulakin-G (a cone snail NT-like peptide), and various reduced-peptide-bond analogs used as research tools for NTSR1 imaging and targeted drug delivery.

Structure/Sequence

Parent Neurotensin: pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-OH (13 aa)

C-Terminal Fragments

• NT(8-13): Arg-Arg-Pro-Tyr-Ile-Leu-OH — minimum fully active sequence; equipotent with or slightly more potent than NT at NTSR1
• NT(9-13): Arg-Pro-Tyr-Ile-Leu — substantially reduced activity
• NT(10-13): Pro-Tyr-Ile-Leu — minimal activity
• NT(11-13): Tyr-Ile-Leu — inactive

N-Terminal Fragments

• NT(1-6): Inactive at neurotensin receptors
• NT(1-8): Inactive
• NT(1-11): Partial activity in some systems
• N-terminal fragments generally lack biological activity, identifying the C-terminal portion as the "message" region

Modified Hexapeptide Analogs

• JMV 449: Pseudopeptide bond replacement ([Lys, ψ(CH2-NH)-Lys, Pro, Tyr, Ile, Leu]) — highly stable agonist
• [D-Arg8]-NT(8-13), [D-Arg9]-NT(8-13): D-amino acid substitutions for peptidase resistance
• NT79, NT86, PD149163: Centrally penetrant analogs used in behavioral research
• ABT-165, SR 142948A, SR 48692: Antagonist scaffolds (some derived from NT fragment framework)

Natural Non-Mammalian Analogs

• Contulakin-G: Cone snail peptide (Conus geographus) with glycosylated NT-like C-terminal sequence; analgesic in mammalian models
• Xenopsin: Frog-skin peptide with C-terminal sequence similar to NT

Mechanism of Action

Minimum Active Sequence

NT(8-13) retains full agonist potency at NTSR1, establishing the C-terminal hexapeptide as the minimum pharmacophore. This has three key implications:

• The N-terminal heptapeptide contributes nothing required for receptor activation
• Medicinal chemistry can focus on the compact hexapeptide scaffold
• Peptidase cleavages within NT(1-7) that don't affect NT(8-13) leave activity intact

Receptor Binding

NT fragments bind:

• NTSR1 (high-affinity): Primary central neurotensin receptor; Gq-coupled; mediates most classical NT effects
• NTSR2 (low-affinity): Binds NT and fragments with lower affinity; distinct pharmacology
• NTSR3 (sortilin): Intracellular sorting receptor; binds NT but does not signal as classical GPCR

Proteolytic Vulnerability

Neurotensin and NT(8-13) are susceptible to multiple peptidases:

• Neprilysin (NEP): Cleaves between residues 10-11 and 11-12
• Endopeptidase 24.15: Cleaves between residues 10-11
• Angiotensin-converting enzyme (ACE): Removes C-terminal dipeptide
• Aminopeptidase: N-terminal cleavage

These peptidases destroy biological activity by fragmenting the C-terminal hexapeptide. Stabilized analogs (reduced peptide bond, D-amino acids, N-methylation) overcome this vulnerability.

Blood-Brain Barrier

Native NT and unmodified NT(8-13) do not cross the BBB efficiently. Peripherally administered native peptide does not produce the full range of central effects. Stabilized, lipophilic analogs (e.g., PD149163) cross the BBB and enable study of central NT receptor pharmacology after systemic administration.

Drug Delivery Applications

NTSR1 is overexpressed in many tumor types (pancreatic, colorectal, prostate, small cell lung cancer), making NT(8-13)-based ligands attractive as tumor-targeting vectors for:

• Radiopharmaceuticals (68Ga-, 177Lu-labeled NT analogs)
• Cytotoxic conjugates
• Imaging agents

Research Summary

Common Discussion Topics

1. Minimum pharmacophore principle — The NT(8-13) result is a paradigm example in peptide pharmacology: the intact peptide often contains "address" residues for metabolic stability or transport, while the true "message" is a compact C-terminal or N-terminal subfragment. Similar discoveries have been made for endomorphin-1, bradykinin, and tuftsin.

2. Stabilization strategies — Reducing peptide bonds, substituting D-amino acids, adding N-methyl groups, or cyclizing converts labile NT fragments into research-useful agents. JMV 449 and related reduced-bond analogs are gold-standard NT receptor research tools.

3. Tumor targeting — NTSR1 overexpression in multiple cancers, combined with NT(8-13)-based ligand availability, has enabled a substantial program of tumor imaging and targeted therapy research. This illustrates how peptide biology can be co-opted for oncology applications via receptor-selective delivery.

4. BBB and centrally-active analogs — The development of NT analogs that cross the BBB after peripheral administration (like PD149163) has enabled study of NT's central effects on dopaminergic signaling, psychosis models, and analgesia in a translatable way.

5. Contulakin-G and natural analogs — That cone snails and frogs produce NT-like peptides (contulakin-G, xenopsin) illustrates convergent evolution of NT-like bioactivities and provides additional templates for analog design.

Related Compounds

• Neurotensin — parent 13-aa peptide
• Neuromedin U — structurally unrelated gut-brain peptide with overlapping functional themes